Stocks News

LAST PRICE
56.3000
TODAY'S CHANGE (%)
Trending Up1.8100 (3.3217%)

Bid / Lots
53.5200/ 1
Ask / Lots
58.9000/ 1
Open / Previous Close
54.4900 / 54.4900
Day Range
Low 52.3700
High 57.0125
52 Week Range
Low 14.1900
High 72.2900
Volume
327,702
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- Apogee Therapeutics to Participate in Upcoming November Investor Conferences, from 9 hours ago by Dow Jones
  9 hours ago by Dow Jones
  Companies Mentioned: APGE
  
  Apogee Therapeutics to Participate in Upcoming November Investor Conferences
  
  SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management will participate at the following investor conferences.
Oct 25, 2024
- DJ Apogee Therapeutics Price Target Maintained With a $87.00/Share by Wedbush, from 11:19AM ET on Friday Oct 25, 2024 by Dow Jones
  11:19AM ET on Friday Oct 25, 2024 by Dow Jones
  Companies Mentioned: APGE
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/APGE/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 25, 2024 11:19 ET (15:19 GMT)
Oct 24, 2024
- Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, from 8:00AM ET on Thursday Oct 24, 2024 by Dow Jones
  8:00AM ET on Thursday Oct 24, 2024 by Dow Jones
  Companies Mentioned: APGE
  
  Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
Oct 16, 2024
- Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting, from 7:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
  7:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
  Companies Mentioned: APGE
  
  Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
  
  SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced an upcoming poster presentation at the American College of Allergy, Asthma & Immunology's (ACAAI) 2024 Annual Scientific Meeting, held in Boston from October 24-28, 2024. The company plans to present data up to 9 months from the ongoing Phase 1 clinical trial of APG777, a novel half-life extended anti-IL-13 antibody for the treatment for atopic dermatitis and other inflammatory diseases.
Oct 7, 2024
- Apogee Therapeutics Insider Sold Shares Worth $2,249,307, According to a Recent SEC Filing, from 3:18AM ET on Monday Oct 07, 2024 by MT Newswires
  3:18AM ET on Monday Oct 07, 2024 by MT Newswires
  Companies Mentioned: APGE
  03:18 AM EDT, 10/07/2024 (MT Newswires) -- Michael Thomas Henderson, Director, Chief Executive Officer, on October 02, 2024, sold 40,000 shares in Apogee Therapeutics (APGE) for $2,249,307. Following the Form 4 filing with the SEC, Henderson has con...

Oct 15, 2024
- DJ MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co., from 6:34AM ET on Tuesday Oct 15, 2024 by Dow Jones
  6:34AM ET on Tuesday Oct 15, 2024 by Dow Jones
  Companies Mentioned: MLTX
Oct 11, 2024
- DJ Edgewise Therapeutics Is Maintained at Overweight by Piper Sandler, from 7:39AM ET on Friday Oct 11, 2024 by Dow Jones
  7:39AM ET on Friday Oct 11, 2024 by Dow Jones
  Companies Mentioned: EWTX
Oct 10, 2024
- DJ Xenon Pharmaceuticals Price Target Announced at $50.00/Share by Raymond James, from 9:05AM ET on Thursday Oct 10, 2024 by Dow Jones
  9:05AM ET on Thursday Oct 10, 2024 by Dow Jones
  Companies Mentioned: XENE
Oct 8, 2024
- Moonlake Immunotherapeutics Insider Sold Shares Worth $9,186,120, According to a Recent SEC Filing, from 4:07PM ET on Tuesday Oct 08, 2024 by MT Newswires
  4:07PM ET on Tuesday Oct 08, 2024 by MT Newswires
  Companies Mentioned: MLTX

Apogee Therapeutics Inc
NASDAQ:APGEUnited States

Search Criteria

Today

Apogee Therapeutics to Participate in Upcoming November Investor Conferences, from 9 hours ago by Dow Jones

Oct 25, 2024

DJ Apogee Therapeutics Price Target Maintained With a $87.00/Share by Wedbush, from 11:19AM ET on Friday Oct 25, 2024 by Dow Jones

Oct 24, 2024

Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, from 8:00AM ET on Thursday Oct 24, 2024 by Dow Jones

Oct 16, 2024

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting, from 7:00AM ET on Wednesday Oct 16, 2024 by Dow Jones

Oct 7, 2024

Apogee Therapeutics Insider Sold Shares Worth $2,249,307, According to a Recent SEC Filing, from 3:18AM ET on Monday Oct 07, 2024 by MT Newswires

Peers Headlines

Oct 15, 2024

DJ MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co., from 6:34AM ET on Tuesday Oct 15, 2024 by Dow Jones

Oct 11, 2024

DJ Edgewise Therapeutics Is Maintained at Overweight by Piper Sandler, from 7:39AM ET on Friday Oct 11, 2024 by Dow Jones

Oct 10, 2024

DJ Xenon Pharmaceuticals Price Target Announced at $50.00/Share by Raymond James, from 9:05AM ET on Thursday Oct 10, 2024 by Dow Jones

Oct 8, 2024

Moonlake Immunotherapeutics Insider Sold Shares Worth $9,186,120, According to a Recent SEC Filing, from 4:07PM ET on Tuesday Oct 08, 2024 by MT Newswires